Kymera reports $1.6B cash; KT-621 Phase 2b AD data by mid-2027, asthma data late-2027

Kymera Therapeutics, Inc.

Preliminary cash, cash equivalents and marketable securities of $1.6B as of Dec 31, 2025; runway into 2029.
KT-621 Phase 2b BROADEN2 trial in AD enrolling, data expected by mid-2027; BREADTH Phase 2b asthma trial initiated, data late-2027.
KT-579 Phase 1 healthy volunteer trial expected to start 1Q26 with data in 2H26; IRF5 degrader for lupus, RA.
At least one new first-in-class oral immunology development candidate to advance towards IND in 2026.
Partnered programs: KT-485/SAR447971 (IRAK4) with Sanofi Phase 1 expected in 2026; CDK2 program with Gilead ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.